leadership team
Joanne Gibbons
Senior Vice President, Head of Regulatory Affairs

Joanne Gibbons serves as Morphic’s Senior Vice President of Regulatory Affairs. In this role, Ms Gibbons leads all regulatory functions and is responsible for overseeing the development and execution of regulatory strategies for Morphic’s development pipeline.

Ms. Gibbons has over 20 years of experience in Regulatory Affairs and Clinical Development, both in the development of novel drugs and the expansion of marketed products. Before joining Morphic in 2022, she served as Vice President and Head of Regulatory Affairs at Codiak Biosciences where she oversaw the regulatory function that led to clinical trials of the first candidates to emerge from Codiak’s engEX™ platform.

Prior to Codiak, Ms. Gibbons was Senior Director, Regulatory Affairs at Wave Life Sciences, and prior to that, she held positions of increasing responsibility in Clinical Development and Regulatory Affairs at Biogen for nearly two decades, culminating as Interim Head of Global Regulatory Strategy. Ms. Gibbons holds a BA from Tufts University.

Back to Leadership Team
Scroll to Top

Contact Us

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8

Morphic is developing small molecule inhibitors of the integrin αvβ8 through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.